“

The significance of these findings is that we find that the individuals who are diagnosed young have a very different disease profile to those that are diagnosed older, and that has important implications for potential treatments in that those individuals that are diagnosed young might benefit more from immunotherapeutic therapies, whereas those that are diagnosed older we might need to look at different therapies that reactivate their sleeping beta cells at the same time as applying immunotherapeutic drugs to prevent any reactivation of an immune response.